

Ottawa


From Disruption to Opportunity


Embracing Change
in Health Care

Sept 4 – 6



Shaw Centre





A Welcome Message From Suzanne McGurn

Welcome to Symposium 2024, our inaugural gathering as Canada's Drug Agency. We have a dynamic and enriching 3-day event planned, filled with insightful discussions and valuable networking opportunities.

As we convene in Ottawa, Canada, we respectfully acknowledge that Symposium 2024 is being held on the traditional, unceded territory of the Anishinabe Algonquin Nation. The city became Ottawa in 1855, with its name derived from the Anishinabe word Adawe, meaning to trade, because of the historical significance of the Ottawa River having long been used as a trade route for many First Nations Peoples. We honour and uphold the inherent and treaty rights of all First Nations, Inuit, and Métis Peoples. In the spirit of reconciliation, we're dedicated to collaborating with Indigenous Peoples and communities, and we value their stewardship of this land.

The past year has been particularly significant for us, as CADTH has evolved into Canada's Drug Agency, building on our expertise in drugs, medical devices, and clinical interventions. Globally, the health care landscape has undergone transformative changes, as well, grappling with challenges such as health professional shortages, data privacy concerns, and rapid advancements in artificial intelligence.

Fortunately, disruption creates opportunity, and Canada's Drug Agency is poised at the forefront, uniquely positioned to help coordinate and align our health system partners – government, the life sciences industry, clinicians, patient groups, Indigenous communities, and other health technology assessment producers. Together, we can leverage our collective expertise and commitment to drive positive change and chart a path toward a brighter future in health care.

On behalf of Canada's Drug Agency, welcome to Symposium 2024. I hope you find inspiration and enjoyment throughout the conference!

Warm regards,



A handwritten signature in black ink that reads "S. McGurn".

Suzanne McGurn

President and CEO, Canada's Drug Agency



Kida nakīwenenāng, mashkikī ne nāgada wābandānig o wābandānawa anishinābe akī, tabakinawewin, ashidj kakina anishinābeg anōdj wendiibājig, wasa kiwedinong wendjibājig ashidj ābitawizijig tanakīwenan. Kakina tanakīwenan anishinābeg kagīge ashidj keyābadj nōngom. Ka akonāmaginewe nānj māmawe wāyabishkīwejig o mashkim wīdōkāzowin kine nisotādeyāng, kakina māmawe, ke wa wenabemin kichi wābadaming kakina kabe dōdāganiwejig anishinābeg odandanakīwenenāng.

Canada's Drug Agency recognizes the traditional territories, rights, and diversity of all First Nations, Inuit, and Métis communities across Canada. Indigenous Peoples have been, and continue to be, excluded from and harmed by Canada's health care systems. In the spirit of reconciliation, Canada's Drug Agency is committed to addressing these inequities alongside Indigenous communities.

The Shaw Centre, where all in-person sessions will take place, is located on the traditional unceded territory of the Anishinabe Algonquin People. Since time immemorial, the people of the Algonquin Nation have been the stewards, keepers, and defenders of the Ottawa River Watershed and its tributaries. Canada's Drug Agency recognizes and deeply appreciates their connection to this place and thanks the generations of people who have taken care of this land.



COVID Policy

The Ontario government no longer requires masking indoors in most areas, including all areas of the Shaw Centre. The COVID policy of Canada's Drug Agency is aligned with provincial health guidance, and in-person participants are not required to wear a mask. Canada's Drug Agency is fully supportive of anyone who decides to wear a mask, and we ask that everyone be kind and respectful of others' choices. If you are experiencing symptoms, please stay home. As an in-person attendee, you have access to all hybrid sessions via the Virtual Attendee Hub live and for 3 months after the Symposium.

Accessibility

The Shaw Centre meets the following codes, standards, and accessibility requirements:

- Ontario Building Code (2006)
- Americans with Disabilities Act (ADA)
- Americans with Disabilities Act Accessibility Guidelines (ADAAG)(2004)
- CAN/CSA-B651 (2004 and draft 2010), Accessible Design for the Built Environment.

Key features include:

- elevator access to all levels
- doorless entry to washrooms
- accessible washroom stalls and individual or family stalls located on all meeting levels
- refuge or rescue assistance areas on each floor above and below the main level
- tactile and braille signage throughout the facility to identify all rooms, including meeting rooms
- entrances that are all accessible and contain automatic door openers
- accessible interior parking on P1 and P2, with an entrance to the Shaw Centre.

Please limit your use of perfumes and personal scents to help ensure an accessible experience for those with fragrance sensitivities.

A high-contrast, large-font version of the printed program is available at the registration desk.

We are striving to make the Symposium more accessible, so we welcome any questions or feedback on how we can make your Symposium experience more comfortable. You can contact the Symposium team at symposium@cda-amc.ca.

Code of Conduct

Canada's Drug Agency welcomes everyone with an interest in evidence-based decision-making about drugs, medical devices, and health systems to our events for productive, meaningful, and respectful discussion and dialogue.

This code of conduct outlines the expectations for staff, attendees, speakers, sponsors, and volunteers (collectively termed "participants") at our Symposium and other events hosted by our organization, including associated activities such as social events, and in the use of social media.

By registering for one of our events, you agree that harassment and disrespectful conduct do not belong at any event hosted by Canada's Drug Agency. Examples of such behaviour may include:

- unwelcome behaviour that demeans or embarrasses a person for any reason
- offensive or inappropriate remarks, gestures, material, or behaviour
- sustained disruption of a speaker
- inappropriate jokes or cartoons including racial or ethnic slurs
- grouping or isolating
- yelling, belittling, or reprimanding in the presence of others
- aggressive behaviour
- sexual harassment or unwelcome attention
- damaging gossip or rumours
- unwarranted or unwanted physical contact
- social media disparagement
- reprisals as a result of making a complaint under this code.

Contact Us to Report an Incident

If you are being harassed, notice that someone else is being harassed, or have any other concerns, please contact a representative from Canada's Drug Agency immediately. Complaints made under this code of conduct will be taken seriously, handled with care, and thoroughly investigated. We will be happy to help participants contact venue security or local law enforcement, provide escorts, or otherwise assist those experiencing harassment to feel safe for the duration of the event. We value your attendance.

Our Commitment

If a participant engages in harassment or disrespectful conduct, Canada's Drug Agency may take any action we deem appropriate, including warning the offender, expulsion from the event without a refund at our discretion, and/or contacting venue security or local law enforcement. Offenders may be excluded from attending future events hosted by Canada's Drug Agency.



Session Types

Symposium 2024 is a hybrid event, offering 2 different types of sessions:



In-Person Sessions: A limited number of sessions are only available to in-person attendees. These sessions will not be recorded.



Hybrid Sessions: All plenary sessions and most concurrent sessions will be fully hybrid, accessible to both in-person and virtual attendees. Hybrid sessions will be recorded and can be viewed for at least 3 months after the Symposium.

Notes

Session Formats

Plenary Session

A plenary session is an opportunity to address all Symposium 2024 attendees at the same time because no other sessions are scheduled at the same time. Simultaneous interpretation is available for all plenary sessions and presenters are invited to speak in English or French.

Early Morning Session

Early morning sessions are 45 minutes long and are scheduled early in the day. In-person attendees are invited to bring their breakfast into the session room.

Workshop

A short course or workshop is an interactive session on a specific topic of interest to producers or users of evidence-based information on drugs and medical devices. Workshops are 3 hours long, including a refreshment break. This year, participation in workshops is included with your registration fee, and advance registration is not required.

Panel Session / Special Session

Panel sessions are 75 minutes long and provide different perspectives on a topic relevant to Symposium 2024 delegates. Canada's Drug Agency is committed to balanced panels, including gender balance, and will not accept manels (all-male panels).

Oral Presentation

An oral presentation will be 15 to 20 minutes long, including time for questions. Oral presentations will be grouped thematically (usually 3 or 4 presentations). The length will be determined by the number of oral presentations during a concurrent session.

Notes



Symposium 2024

Thank You

We gratefully acknowledge the contribution of our sponsors to the success of Symposium 2024. This event could not continue to grow and improve without you!

Platinum



Gold



Silver



Bronze



We would also like to acknowledge the support of our funders. Canada's Drug Agency activities, programs, and services, including Symposium 2024, are made possible through financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, the Northwest Territories, Nova Scotia, Nunavut, Ontario, Prince Edward Island, Saskatchewan, and Yukon.

Transforming the prescription drug landscape



Building a pan-Canadian “All Drugs, All People” pharmaceutical data foundation

Visit our booth to learn about

- **Our new Pharmaceutical Data Tool**, providing information on the design, payment structures and formularies of public drug programs in Canada
- How CIHI is enhancing the collection and use of **real-world evidence on drugs for rare diseases**

Friday, September 6

7:45 to 8:30 a.m.

Join our early-morning session

and discover how CIHI’s data and tools can improve information on drugs for rare diseases

cihi.ca



Canadian Institute
for Health Information

Institut canadien
d'information sur la santé



Download the Symposium Event App



Scan and Download

Explore the complete Symposium schedule, including plenary sessions, workshops, special sessions, and more.


Step 1

Download the “Cvent Events” app from your mobile device’s App Store.


Step 2

Search “CDA-AMC Symposium 2024” within the Cvent App.

Step 3

Tap download  icon beside “CDA-AMC Symposium 2024.”

Step 4

Tap arrow  to log in with your first name, last name, and email.

Step 5

Complete verification and log in.



Need assistance?

Look for people wearing this — we’re here to help.

CANADIAN MARKET ACCESS SUCCESS STARTS WITH THE RIGHT PARTNER

Outstanding full-service market access support:

- ✓ Reimbursement and pricing strategy
- ✓ HTA, public and private payer dossiers
- ✓ Advisory boards
- ✓ Price negotiations
- ✓ Advocacy and stakeholder engagement

Leveraging EVERSANA's global HEOR capabilities to maximize success in Canada:

- ✓ Team of 150+ HEOR professionals, including former senior CDA-AMC staff
- ✓ Thought leaders in evidence synthesis (SLR/ITC)
- ✓ World-class economic modelling team
- ✓ Experts in biostatistics and RWD/RWE
- ✓ 100's of global and Canadian submissions and over 20 years of experience



EVERSANA.COM



Symposium 2024


Wednesday, September 4

	Registration Desk Open 7:30 a.m. to 7:30 p.m.	Level 3
07:30 a.m. – 08:30 a.m.	Breakfast	Level 3
08:30 a.m. – 11:30 a.m.	Workshops	Level 2
09:15 a.m. – 10:15 a.m.	Special Session	Level 2
10:15 a.m. – 10:45 a.m.	Networking Break	Level 3
10:45 a.m. – 11:30 p.m.	Special Session	Level 2
11:30 p.m. – 12:15 p.m.	Lunch Break	Level 3
12:15 p.m. – 01:30 p.m.	Special Session	Level 2
12:15 p.m. – 03:15 p.m.	Workshops	Level 2
01:30 p.m. – 02:00 p.m.	Networking Break	Level 3
02:00 p.m. – 03:15 p.m.	Special Session	Level 2
03:30 p.m. – 04:45 p.m.	Special Session	Level 2
04:45 p.m. – 05:30 p.m.	Student Meet and Greet	Level 1
04:45 p.m. – 05:30 p.m.	Patient and Caregiver Meet and Greet	Level 3
05:15 p.m. – 07:00 p.m.	Welcome Reception and Scientific Poster Exhibition	Level 3

Thursday, September 5

	Registration Desk Open 7:30 a.m. to 5:30 p.m.	Level 3
07:30 a.m. – 08:30 a.m.	Breakfast	Level 3
07:45 a.m. – 08:30 a.m.	Early Morning Sessions	Level 2
08:45 a.m. – 09:30 a.m.	Official Opening	Level 3
09:30 a.m. – 10:45 a.m.	Opening Plenary	Level 3
10:45 a.m. – 11:15 a.m.	Networking Break	Level 3
11:15 a.m. – 12:30 p.m.	Panel Sessions	Levels 2 and 3
12:30 p.m. – 01:30 p.m.	Lunch Break	Level 3
01:30 p.m. – 02:45 p.m.	Panel Session	Levels 2 and 3
01:30 p.m. – 02:45 p.m.	Oral Presentations	Level 2
02:45 p.m. – 03:15 p.m.	Networking Break	Level 3
03:15 p.m. – 04:30 p.m.	Panel Sessions	Levels 2 and 3
06:00 p.m. – 09:00 p.m.	Symposium Dinner	Level 4

 **Friday, September 6**

 Registration Desk Open 7:30 a.m. to 3:00 p.m.	Level 3
07:30 a.m. – 8:45 a.m.	Breakfast Level 3
07:45 a.m. – 8:30 a.m.	Early Morning Sessions Levels 2 and 3
08:45 a.m. – 10:00 a.m.	Panel Sessions Levels 2 and 3
10:00 a.m. – 10:30 a.m.	Networking Break Level 3
10:30 a.m. – 11:30 p.m.	Oral Presentations Levels 2 and 3
11:30 p.m. – 12:00 p.m.	Networking Break Level 3
12:00 p.m. – 01:15 p.m.	Closing Plenary Level 3
01:15 p.m. – 01:30 p.m.	Student Poster Award and Official Closing Level 3
01:30 p.m. – 02:30 p.m.	Closing Reception Level 3

HTA Gives Back

Canada’s Drug Agency launched the HTA Gives Back initiative in 2019 as a way to provide a lasting benefit to the communities where our Symposium is held. Rather than providing thank you gifts to our plenary speakers, abstract reviewers, and other volunteers, we make a charitable donation to a local registered charity.

For 2024, the charity is Tungasuvvingat Inuit, an Inuit-specific urban services provider that offers community supports for Inuit throughout Ontario. According to the 2016 census, 6,870 Inuit now live in Ontario, with the majority living in the National Capital region, making it the largest Inuit community outside of the North.

Symposium attendees, both in-person and virtual, can help support this great cause. Just take a few moments to fill in a short attendee survey. For every person who completes the survey, we’ll donate an additional \$5 to Tungasuvvingat Inuit.


Learn more about Tungasuvvingat Inuit and their services at tiontario.ca



Notes



Shaw Centre




2

55 Colonel By Drive




Look for people wearing this — we're here to help.

Event Map



Look for people wearing this — we're here to help.



The background of the image is a vibrant sunset or sunrise scene. The sky is filled with a gradient of colors, from deep blue at the top to bright yellow and orange near the horizon. A prominent, bright, curved light path, possibly a contrail or a reflection, arcs across the lower half of the frame. The overall texture is grainy and high-contrast.

Networking Events

Your most trusted consulting partner for strategic end-to-end market access and launch solutions



Our comprehensive service offerings include:



Strategic Pricing and Market Access Assessments



PMPRB HDAP Submissions, Regulatory Filings and Investigations



Payer Research and Advisory Boards



Strategic Reimbursement Submission Development and Reviews



Clinical Summaries and Systematic Literature Reviews



Health Economic and Budget Impact Model Builds, Adaptations, and Reports



pCPA/PLA Negotiation Training, Strategic Planning and Direct Payer Engagement



Policy Research, White Papers, Posters and Manuscripts



Public & Private Claims Databases and Drug Listing/Negotiated Agreements Data



Advanced Data Analytics and Real-World Evidence Studies

Contact PDCI's Managing Director Kaitlyn Proulx at Kaitlyn.Proulx@pdci.ca to customize your market access solutions today.

Networking Events

Student Meet and Greet

📅 Wednesday, September 4 ⌚ 4:45 p.m. – 5:30 p.m. 📍 Level 1 – Colonel By Foyer

Students attending the Symposium in person are invited to meet other student attendees and senior staff from Canada's Drug Agency. Light refreshments will be available.

Patient and Caregiver Meet and Greet

📅 Wednesday, September 4 ⌚ 4:45 p.m. – 5:30 p.m. 📍 Level 3 – Canada Hall 2

Caregivers and representatives of patient groups attending the Symposium in person are invited to meet one another and senior staff from Canada's Drug Agency. A cash bar and light refreshments will be available.

Welcome Reception and Scientific Poster Exhibition

📅 Wednesday, September 4 ⌚ 5:15 p.m. – 7:00 p.m. 📍 Level 3 – Parliament Foyer


The Welcome Reception features scientific posters and the opportunity to meet and talk with the authors in person about their work. The 2024 recipients of Canada's Drug Agency recognition awards will be introduced. A cash bar and light refreshments will be available.

Symposium Dinner

📅 Thursday, September 5 ⌚ 6:00 p.m. – 9:00 p.m. 📍 Level 4 – Trillium Ballroom

Join us for an evening of casual networking and camaraderie at the Symposium Dinner. After a day of great speakers, engaging sessions, and insightful discussions, unwind and connect over a beverage and a good meal. Enjoy the food and the conversation and be inspired by our guest speaker, Dr. Kwadwo Kyeremanteng. He is the Department Head of Critical Care at The Ottawa Hospital, host of the *Solving Healthcare* podcast, and author of *Unapologetic Leadership*. His talk will focus on the need for change in health care and the important role of leaders in embracing change. The Symposium Dinner is the perfect opportunity to forge new connections and deepen existing ones in a relaxed and welcoming atmosphere. See you there!

Notes



The background of the slide is a photograph of a sunset or sunrise. The sky is a mix of deep blue, orange, and yellow. A bright, curved light path, possibly a contrail or a reflection, arcs across the lower half of the image. The overall texture is grainy, suggesting a high-resolution or digital art style.

Plenary Sessions

Excellence in HEOR and Market Access

SUBMISSION TO PAYERS

- Development of Key Components
- Preparation of Submission to Payers
- Both Public and Private Payers

STRATEGIC CONSULTING

- In-licensing Market Assessment
- Critical Analysis of Submission Dossier
- Environmental Scan

HEALTH ECONOMICS

- Economic Models and Adaptations
- Budget Impact Analysis
- Cost of Illness Studies

EVIDENCE SYNTHESIS

- Literature Review
- Indirect Treatment Comparisons
- Clinical Evidence Dossiers

REAL-WORLD EVIDENCE

- Observational Studies
- Database Analyses
- Interview with Clinical Experts



The Patient's Voice at the Core of Health Care Decisions
Effective patient-centered evidence generation



Plenary Sessions

Official Opening

📅 Thursday, September 5 ⌚ 8:45 a.m. – 9:30 a.m. ET 📍 Level 3 – Canada Hall 1

Join Suzanne McGurn, President and CEO of Canada's Drug Agency, and special guests for the Official Opening of Symposium 2024. Ms. McGurn will welcome virtual and in-person attendees, describe some of the Symposium highlights, and unveil the branding of the new agency.

Opening Plenary

📅 Thursday, September 5 ⌚ 9:30 a.m. – 10:45 a.m. ET 📍 Level 3 – Canada Hall 1

Introducing Canada's Drug Agency

The Government of Canada announced that Canada's Drug Agency would build on and expand the mandate and functions of CADTH. Join us for a dynamic plenary focused on 1 of the new drug agency's core missions: system coordination and alignment. An esteemed panel will delve into the pivotal role of Canada's Drug Agency within the nation's pharmaceutical landscape, exploring shared priorities and collaboration opportunities to boost system efficiency. Discover how all system contributors will navigate disruption, embrace change, and innovate to meet the evolving needs of patients and decision-makers in Canada.



Patrick Dicerni is the Assistant Deputy Minister of the Health Programs and Delivery division and Executive Officer, Ontario Public Drug Programs, at the Ontario Ministry of Health and Long-Term Care. Prior to his current roles, Patrick worked in the Deputy Minister's Office as the Director of Policy and Delivery. He played an important role in implementing the ministry's policy agenda and delivering on a number of key ministry priorities. During his time in the Deputy Minister's Office, he served 2 ministers and provided strategic advice and support to 3 deputy ministers. Before joining the Ministry of Health, Patrick held a number of increasingly senior positions at the Ministry of Children and Youth Services.

Notes



Opening Plenary



Bettina Hamelin, PharmD, EMBA, is a globally renowned researcher and life sciences executive who brings more than 30 years of experience in academia, industry, and not-for-profit organizations to her current role as President of Innovative Medicines Canada. In this role, Dr. Hamelin is dedicated to enhancing access to innovative medicines for Canadians while advancing Canada's position as an attractive destination for life sciences investments, high-value jobs, and new clinical trials. Driven by her commitment to improving the health and well-being of all people in Canada, Dr. Hamelin believes collaboration and partnership are essential to the future of health care innovation in Canada. With an Executive MBA in Healthcare from the Sauder School of Business at the University of British Columbia, she is uniquely positioned to work alongside health system partners to find novel solutions to complex challenges.



Daniel MacDonald is the Director General responsible for advancing the Government of Canada's pharmaceuticals policy agenda in partnership with Canada's Drug Agency, and for leading the implementation of the recently announced National Strategy for Drugs for Rare Diseases. Prior to this role, Daniel held various executive positions at Finance Canada, Transport Canada, and Natural Resources Canada.



Suzanne McGurn is the President and CEO of Canada's Drug Agency, leading the organization to provide objective evidence for informed decisions on drug and health technology use. Joining the organization in July 2020, she is focused on transformative changes to support evidence-based health decisions. Suzanne worked for 17 years as a registered nurse in clinical care before moving to government, where she held various assistant deputy minister roles in Ontario, focusing on public drug programs and health human resources strategy. She has built strong relationships with patients, officials, and industry, gaining deep insights into Canada's health systems. Suzanne led the implementation of the pan-Canadian Pharmaceutical Alliance (pCPA) and was its first chair. She is also on the board of the International Network of Agencies for Health Technology Assessment (INAHTA). Suzanne holds a BScN and an MPA from Queen's University.

Notes

Opening Plenary



Dominic Tan is the acting CEO of the pCPA. He brings a wealth of experience to the role, having been involved with the pCPA since it was established in 2010. He has been part of the evolution of the organization, and formerly held the titles of Deputy CEO and Senior Director of Negotiations and Outcomes. Dominic has a background in business administration, which has provided a solid foundation for navigating the complex landscape of Canada's pharmaceutical system. Prior to joining the pCPA, Dominic held roles with the British Columbia Ministry of Health, where he managed the commercial aspects of pharmaceutical drugs and devices, including negotiations and strategic projects. The pCPA negotiates drug costs with pharmaceutical companies on behalf of 14 publicly funded drug programs (provincial, territorial, and federal programs) in Canada. Its mandate is to enhance patient access to clinically relevant and cost-effective drug treatment options.



Guillaume Couillard has been the Director General at the Patented Medicine Prices Review Board since April 2023, overseeing day-to-day operations. Previously, he served as the Director of Regulatory Affairs and Outreach (Dec. 2019 - April 2023), managing projects and investigations under the Patent Act. From June 2014 to Dec. 2019, he was the Director of Board Secretariat, Communications, and Strategic Planning at the Canadian Patented Medicine Prices Review Board, handling hearings, media communications, and strategic planning. Guillaume also worked at the Competition Bureau from 2001 to 2014, serving as Major Case Director and Strategic Advisor (Oct. 2012 - June 2014), managing projects under the Competition Act. He holds a License in Common Law (May 2001) and a Degree in Civil Law (May 2000) from the University of Ottawa.



Moderator

Beth Kidd is the Executive Director of Health Coalition of Alberta, representing more than 120 health charities, patient groups, health associations and individual members. In this capacity, she advocates on priorities such as health equity, access to care, access to medications, and patient engagement. Beth has spent the majority of her career in the health charity sector, although she came to the Health Coalition of Alberta from the corporate world. Beth is a life long volunteer with many charities, political parties, and community groups. Currently, she volunteers with Research Canada's Board of Directors, the Patient and Community Advisory Committee at Canada's Drug Agency, Dementia Network Calgary's Strategic Council, and Alberta's International Medical Graduates Association. A patient advocate herself, she is also one of the leaders with Migraine Warriors Alberta and a caregiver to her loved ones.



Closing Plenary

📅 Friday, September 6 ⌚ 12:00 p.m. – 1:15 p.m. ET 📍 Level 3 – Canada Hall 1

From Disruption to Opportunity: How AI is Changing Health Care and HTA

From drug development to diagnostic imaging to robotic surgery, artificial intelligence (AI) is having a profound effect on health care. AI is also changing how HTA organizations do their work and challenging them to consider different elements when assessing technologies that use AI. An international panel of senior HTA leaders will share their insights and experiences on how AI is being incorporated into HTA processes and how HTA can effectively address AI to create opportunities for improved patient outcomes and cost-effective health care delivery. They will discuss why disruptive innovation is needed, the potential risks and benefits of AI, and what jurisdictions around the world are doing to adapt to these new challenges. Attendees will gain valuable insights into the role of HTA in embracing change and driving innovation in health care. They will leave with a deeper understanding of how HTA can help health care systems adapt to disruptions, seize opportunities, and ultimately improve patient outcomes and the sustainability of health care delivery.



Nick Crabb is the Chief Scientific Officer at the National Institute for Health and Care Excellence (NICE). Before joining NICE in 2010, he had a 20-year career in analytical science, process technology, and general management in the chemical, pharmaceutical, and contract laboratory industries. At NICE, he initially established and managed the Diagnostics Assessment Programme and later became Programme Director of Scientific Affairs. Nick now oversees NICE's Science, Evidence, and Analytics Directorate, focusing on evaluating technologies and interventions for clinical, public health, and social care guidance. His expertise includes HTA of novel products like cell and gene therapies, and evaluation methods for antimicrobials. He led a collaborative pilot project with NHS England to develop innovative models for antimicrobial evaluation and purchase, and collaborates with national and international regulators to align regulatory and HTA processes.



Irena Guzina holds a PharmD, as well as a master's degree in quality control and public health. She has been a member of the INAHTA board of directors since 2023 and is a co-chair of INAHTA's Scientific Program. Irena also works as a medical assessor at the Department for the Assessment of Medical Procedures at the French National Authority for Health. She has more than 10 years of experience in HTA of medical procedures and diagnostic tests, as well as international project management. Notably, she coordinated EUnetHTA's activities on postlaunch evidence generation and real-world data from 2016 to 2021.

Closing Plenary



Pascale Lehoux holds a bachelor's degree in industrial design and a PhD in public health from the Université de Montréal. After completing postdoctoral training in Science and Technology Dynamics at the University of Amsterdam and CÉTS, she began her academic career in 1998 at the Université de Montréal's Department of Health Administration. She has published 2 books and more than 165 peer-reviewed articles, and has developed numerous knowledge mobilization initiatives. She held the Canada Research Chair in Health Innovations from 2005 to 2015. Her research program, In Fieri, ranked 22nd in the Canadian Institutes of Health Research's Foundation Scheme. In 2019, she received the 30th Anniversary Medal from CADTH, and received the Peggy Leatt Award from the University of Toronto in 2021. She served on the Institut national d'excellence en santé et en services sociaux (INESSS) board of directors from 2018 to 2023 and has been its Scientific Vice-President since August 1, 2023.



Nicole Mittmann is the Chief Scientist and Vice-President of Scientific Evidence, Methodologies, and Resources at Canada's Drug Agency. She promotes active learning, ensures scientific rigour and quality, links science to strategy, and disseminates evidence through the Canadian Journal of Health Technologies. Leading the agency's shared science groups – including Science and Methods, Health Economics, Research Information Services, and Publishing – Dr. Mittmann has a strong background in economic evaluations, outcomes research, and drug-patient safety. Her methodologies include large database analysis, economic methodologies, and decision analyses. Dr. Mittmann earned an MSc and PhD in Pharmacology from the University of Toronto, where she is an assistant professor in the Department of Pharmacology and Toxicology and cross-appointed to the Institute for Health Policy, Management, and Evaluation. She is also an associate scientist at Sunnybrook Health Sciences Centre.



Dan Ollendorf is the Chief Scientific Officer and Director of HTA Methods and Engagement at the Institute for Clinical and Economic Review (ICER), with responsibility for internal health economics capacity and program of external collaboration, as well as collaboration with international HTA bodies and other interested parties on key process and methods topics. From 2018 to 2023, Dr. Ollendorf served as the Director of Value Measurement and Global Health Initiatives at the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center, where he focused on value assessment methods, drug pricing policy, and building international capacity for and interest in HTA. In addition to his ICER responsibilities, Dr. Ollendorf maintains a faculty position at CEVR and continues to teach in the center's graduate certificate program.

How strong is your evidence?

With the right evidence, you can find the right path to achieve your goals

- Define unmet need
- Demonstrate value
- Reduce uncertainty
- Inform negotiations

IQVIA offers the most comprehensive set of solutions for access, medical and HEOR in Canada.

Strategy & Access

Health Economics & HTA

Outcomes Research


IQVIA creates intelligent connections to deliver powerful insights to the life sciences industry with speed and agility. Innovation in real-world evidence is at the core of what we do.

Visit our booth in Canada Hall 2 (3rd level) to talk with our experts.



Learn more about what we do





The background of the page is a photograph of a sunset or sunrise. The sky is a mix of deep blue, orange, and yellow. A bright, curved light path, possibly a reflection or a lens flare, arcs across the lower half of the image. The word "Schedule" is printed in white, bold, sans-serif font in the middle-right area of the image.

Schedule



Symposium 2024



Wednesday, September 4



Registration Desk Open 7:30 a.m. to 7:30 p.m.

Breakfast

Workshops

8:30 a.m. – 11:30 a.m.

Qualitative Thinking and Best Practices in HTA: Unlocking Opportunities for Policy Impact

📍 Level 2 – Room 206 🧑 In-Person Only

Francesca Brundisini, Jamie Anne Bentz, Viviane Grandpierre, and Elijah Herington, Canada's Drug Agency

Innovative Approaches to Real-World Evidence Generation: Selecting the Appropriate Study Design to Answer Your Evidence Needs

📍 Level 2 – Room 205 🖥 Hybrid

Calum Neish, Brad Millson, and Jillian Murray, IQVIA Solutions Canada Inc.

Special Session

9:15 a.m. – 10:15 a.m.

Opening Doors to Meaningful Engagement

📍 Level 2 – Room 207 🖥 Hybrid

Peter Dyrda, Sudha Kutty, and Nicole Mittmann, Canada's Drug Agency

☕ Networking Break ☕

Special Session

10:45 a.m. – 11:30 a.m.

New Initiatives in Health Economics at Canada's Drug Agency

📍 Level 2 – Room 207 🖥 Hybrid

Karen Lee and Alex Haines, Canada's Drug Agency

Notes



 **Wednesday, September 4**

 **Lunch Break** 

Special Session

12:15 p.m. – 1:30 p.m.

A New Era of Innovation and Collaboration in PMDE

 Level 2 – Room 207  Hybrid

Tarry Ahuja, Nadine Sulatycky, and Emily Farrell, Canada's Drug Agency; Virgine Giroux, Merck Canada Inc.

Workshops



12:15 p.m. – 3:15 p.m.

Unlocking Ethics in HTA: Exploring Practice and Impact

 Level 2 – Room 206  Hybrid

Renata Axler, Deirdre DeJean, and Ana Komparic, Canada's Drug Agency; Avram Denburg, The Hospital for Sick Children

An Introduction to Health Technology Assessment

 Level 2 – Room 205  Hybrid

Don Husereau, University of Ottawa

 **Networking Break** 

Special Session

2:00 p.m. – 3:15 p.m.

Canada's Drug Agency Initiatives in Drugs for Rare Diseases

 Level 2 – Room 207  Hybrid

Nicole Mittmann, Trish Caetano, and Helen Mai, Canada's Drug Agency; Matt McDonald and Andrew Taylor, Health Canada

Special Session

3:30 p.m. – 4:45 p.m.

Advancing HTA Methods

 Level 2 – Room 207  Hybrid

Farah Husein, Deirdre DeJean, Saunya Dover, Renata Axler, and Viviane Grandpierre, Canada's Drug Agency



Bridging the gap to faster & better access



Transform Healthcare Economics

ACCELERATE ACCESS

IDENTIFY & IMPLEMENT SUSTAINABLE PRICING MODELS

OPTIMIZE RESOURCES

How We Make It Happen

Library



Comprehensive insights to support price negotiation strategy.

Access the largest digital library of real-world drug pricing and rebate agreements powered by AI.

Simulator



Transform your data into decisions.

Sophisticated drug pricing and rebate simulator for pharma and healthcare payers.

Analytics



Automated contracting solution.

Next-generation rebate and revenue management software tailored exclusively for optimizing and managing drug budget.

Together we can transform the healthcare of tomorrow.

Come and see us at the CDA Symposium 2024

or visit lyfegen.com to discover more.





Symposium 2024



Thursday, September 5



Registration Desk Open 7:30 a.m. to 5:30 p.m.

Breakfast

Early Morning Sessions

7:45 a.m. – 8:30 a.m.

Operationalizing Outcomes-Based Agreements in Canada

📍 Level 2 – Room 205 🖥️ Hybrid

Kate Harback, Institute of Health Economics

The Growing Problem of Drug Shortages: Understanding Their Impact on Research, Patients, and Health Care Systems

📍 Level 2 – Room 206 🖥️ Hybrid

Mina Tadrous, University of Toronto; Stephanie Di Trapani, Health Canada; Saad Ahmed, University of Toronto

Opening

8:45 a.m. – 9:30 a.m.

Official Opening

📍 Level 3 – Canada Hall 1 🖥️ Hybrid

Suzanne McGurn, President and CEO, Canada’s Drug Agency

Notes

 **Thursday, September 5**

Opening Plenary

9:30 a.m. – 10:45 a.m.

Introducing Canada’s Drug Agency

 Level 3 – Canada Hall 1  Hybrid

The Government of Canada announced that Canada’s Drug Agency would build on and expand the mandate and functions of CADTH. Join us for a dynamic plenary focused on one of the new drug agency’s core missions: system coordination and alignment. An esteemed panel will delve into the pivotal role of Canada’s Drug Agency within the nation’s pharmaceutical landscape, exploring shared priorities and collaboration opportunities to boost system efficiency. Discover how all system contributors will navigate disruption, embrace change, and innovate to meet the evolving needs of patients and decision-makers in Canada.

- **Guillaume Couillard**, Executive Director, Patented Medicine Prices Review Board
- **Patrick Dicteri**, Assistant Deputy Minister Health Programs and Delivery Division and Executive Officer, Ontario Public Drug Programs, Ontario Ministry of Health and Long-Term Care
- **Bettina Hamelin**, President, Innovative Medicines Canada
- **Beth Kidd**, Executive Director, Health Coalition of Alberta (Moderator)
- **Daniel MacDonald**, Director General, Office of Pharmaceutical Management Strategies and Drugs for Rare Diseases, Health Policy Branch, Health Canada
- **Suzanne McGurn**, President and CEO, Canada’s Drug Agency
- **Dominic Tan**, Acting CEO, pan-Canadian Pharmaceutical Alliance

Notes



📅 Thursday, September 5

☕ Networking Break ☕

Panel Sessions

11:15 a.m. – 12:30 p.m.

Innovation in the Pharmaceutical Ecosystem

📍 Level 3 – Canada Hall 1 🖥️ Hybrid

Peter Dyrda, Canada's Drug Agency; Karen Reynolds, Health Canada; Gail Attara, GI Society; Sudha Kutty, Canada's Drug Agency (Moderator); Dominic Tan, pCPA

Cultivating INDequity Through Indigenous-Led Pathways to E-Health Using an Innovative P3 Model to Partnership

📍 Level 2 – Room 206 🖥️ Hybrid

Vanessa Ambtman-Smith, Western University; Mehmood Alibhai, Boehringer Ingelheim Canada Ltd.

Developing a Real-World Readiness Framework for Patient Support Programs: A Collaborative Approach

📍 Level 2 – Room 201 🧑 In-Person Only

Daniel Zimskind, ZS; Bryan Asher, Shoppers Drug Mart; Sarah Power, Takeda; Barry Stein, Colorectal Cancer Canada

Breaking Barriers: Tackling Challenges in Mental Health Drug Health Technology Assessments

📍 Level 2 – Room 207 🖥️ Hybrid

Matthew Dick, IQVIA Solutions Canada Inc. (Moderator); Don Husereau, University of Ottawa; Roger McIntyre, University of Toronto

Delivering Precision Oncology as Standard of Care – How Genomic Testing Is Driving Better Patient Outcomes and Increased Access to Clinical Trials for Cancer Patients

📍 Level 2 – Room 205 🖥️ Hybrid

Michael Carter and Tanya Gillian, Nova Scotia Health; Ravi Ramjeesingh, Dalhousie University

 **Thursday, September 5**

 **Lunch Break** 

Panel Sessions



1:30 p.m. – 2:45 p.m.

Enhancing Rare Disease Registries for Health Technology Assessment: Current Initiatives and Preliminary Findings

 Level 3 – Canada Hall 1  Hybrid

Trish Caetano (Moderator), Claudia Sikorski, Viktoria Roman, and Sinwan Basharat, Canada's Drug Agency; Alfonso Iorio, McMaster University

A Researcher–Policy–Maker Partnership to Design, Implement, and Evaluate Canada's First Universal Contraception Subsidy: Impact of British Columbia's Contraception Subsidy

 Level 2 – Room 201  In-Person Only

Laura Schummers, University of British Columbia; Wendy V. Norman, University of British Columbia; I Fan Kuo, BC Ministry of Health; Martin Odendaal, BC Ministry of Health; Michael Law, University of British Columbia; Bonnie Henry, BC Ministry of Health (Moderator)

Oral Presentations

1:30 p.m. – 2:45 p.m.

Oncology

 Level 2 – Room 207  Hybrid

The Growing Importance of Companion Diagnostics on Cancer Therapeutics and Funding

Scott Gavura, Ontario Health (Cancer Care Ontario)

PROgress Tracker Breast Cancer Registry: Diverse Real-World Evidence to Inform HTA via a Patient Reported Outcomes Longitudinal Study of Canadian Breast Cancer Survivors

Kimberly Carson and Shaniah Leduc, Breast Cancer Canada

Patient Values Project: Understanding Patient Preferences for Cancer Treatments to Inform a Framework for Incorporating Patient Values Into Health Technology Assessment

Deborah A Marshall, University of Calgary

Timelines of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada

Nigel Rawson, Macdonald-Laurier Institute



📅 Thursday, September 5

Oral Presentations

1:30 p.m. – 2:45 p.m.

Hot Topics

📍 Level 2 – Room 206 🖥️ Hybrid

Navigating Growth: Ontario's CAR T-Cell Therapy Program
Cassandra McKay, Ontario Health (Cancer Care Ontario)

Developing a Drug Shortages Predictive Model Using Real-World Canadian Drug Utilization
Arany Santhireswaran, University of Toronto

Improving Equity Assessment in Drug Policy Decisions
Jolanta Piszczek, University of British Columbia

Therapeutic Value of Drugs for Orphan Diseases
Joel Lexchin, York University

Artificial Intelligence and Digital Health

📍 Level 2 – Room 205 🖥️ Hybrid

Homecare Innovations: At the Intersection of Technology and Humanity
Corelia Kostovic and Marie-Helene Raymond, INESSS

A National Standard for Cyber Resiliency in Health Care
Siri Chunduri and Jonathan I. Mitchell, HealthCareCAN

Clinical Practice in a Digital Health Environment: New Best Practice Guideline
Lauren Bailey, Registered Nurses' Association of Ontario (RNAO)

Partnering Together for Integrated Person- and Family-Centric Care Across the Mental Wellness Care Continuum: Stepped Care 2.0 in the Northwest Territories
Danielle Impey, Mental Health Commission of Canada

🍷 **Networking Break** 🍷

Notes

 **Thursday, September 5**

Panel Sessions

3:15 p.m. – 4:30 p.m.

Disruptive Partnership: Charting the Future of Pan-Canadian Data and Analytics

 Level 2 – Room 207  Hybrid



Elena Lungu, Canada's Drug Agency (Moderator); Connie Côté, Health Charities Coalition of Canada; Brent Diverty, Canadian Institute for Health Information; Kimberlyn McGrail, HDRN Canada; Brad Millson, IQVIA Solutions Canada Inc.

Accelerating Access: Leveraging Target Zero to Expedite Time to Access for New Therapies

 Level 3 – Canada Hall 1  Hybrid

Lana Duan, MORSE Consulting Inc.; Beth Kidd, Health Coalition of Alberta; Imran Ali, Bristol-Myers Squibb Canada; Sudha Kutty, Canada's Drug Agency; Katherine Scott, Morse Consulting Inc. (Moderator)

Incorporating the Child's Perspective in Health Technology Assessment in Canada

 Level 2 – Room 201  In-Person Only

Jesse Elliot, Canada's Drug Agency; Brittany Humphries, McMaster University; Wendy Ungar, Hospital for Sick Children Research Institute; Feng Xie, McMaster University

Rethinking How We Do HTA – Toward a Broader Health System Approach

 Level 2 – Room 206  Hybrid

Leslie Anne Campbell, Dalhousie University; Craig Mitton, UBC; Laura Weeks, Canada's Drug Agency; Dan Coulombe, Department of Health, New Brunswick; Lesley Dunfield (Moderator), Institute of Health Economics

Advancing Patient Engagement and Impact in Canada's Drug Agency Deliberative Process: A Multistakeholder Collaboration

 Level 2 – Room 205  Hybrid

William Dempster, 3Sixty Public Affairs (Moderator); Gail Attara, GI Society; Bonnie Macfarlane, Janssen Inc.; Nicole Mittmann, Canada's Drug Agency; Jessy Ranger, Myeloma Canada; Nancy Zorzi, Mood Disorders Society of Canada



Symposium 2024

📅 Thursday, September 5

Networking Event

6:00 p.m. – 9:00 p.m.

Symposium Dinner

📍 Level 4 – Trillium Ballroom 👤 In-Person Only

Join us for an evening of casual networking and camaraderie at the Symposium Dinner. After a day of great speakers, engaging sessions, and insightful discussions, unwind and connect over a beverage and a good meal. Enjoy the food and the conversation, and be inspired by our guest speaker, Dr. Kwadwo Kyeremanteng. He is the Department Head of Critical Care at the Ottawa Hospital, host of the *Solving Healthcare* podcast, and author of *Unapologetic Leadership*. His talk will focus on the need for change in health care and the important role of leaders in embracing change. The Symposium Dinner is the perfect opportunity to forge new connections and deepen existing ones in a relaxed and welcoming atmosphere. Dinner ticket required.

Your partner in navigating Health Technology Assessments

At Quadrant, we specialize in creating and adapting health economic models to support market access. With over two decades of consulting experience, we take pride in conducting rigorous scientific research for the creation of robust economic tools.



Contact our modeling experts:

Debbie Becker Michele Kohli
www.quadrantthe.com



MORSE CONSULTING'S

UNPARALLELED PAYER AND HTA EXPERTISE

SUPPORTS CLIENTS AT EVERY STEP OF THEIR
PRODUCT LAUNCH LIFE CYCLE, FROM EARLY-STAGE
EVIDENCE STRATEGY TO REIMBURSEMENT AND
POST-MARKET INITIATIVES.

OTTAWA | TORONTO
MORSECONSULTING.CA

MORSE | DECIPHERING
CONSULTING MARKET
ACCESS





Symposium 2024



Friday, September 6



Registration Desk Open 7:30 a.m. to 3:00 p.m.

Breakfast

Early Morning Sessions

7:45 a.m. – 8:30 a.m.

Health Economics Oral Presentations

📍 Level 2 – Room 201 🧑 In-Person Only

Severity Weighting of QALYs in Economic Evaluation: Why, How, and Where Next?

Shehzad Ali, Western University

Using a 1-Day Living Kidney Donor Evaluation Process to Boost Kidney Transplant Rates: An Early Economic Evaluation

Andrew Scarffe, Ottawa Hospital Research Hospital

Equity of Financial Protection For Health in High-Income Countries: A Scoping Review of Methodologies and Values

Edward Xie, University of Toronto

Real-World Evidence (RWE): Empowering Patient Advocacy Groups to Co-Design Registries That Fill a Data Gap for Their Community

📍 Level 2 – Room 206 🖥️ Hybrid

Shawn Paron, Alzheimer Society of Ontario; Christa Studzinski, Ontario Brain Institute

Insight Into How CIHI's Data and Tools Can Be Leveraged to Improve the Information Available on Drugs for Rare Diseases

📍 Level 2 – Room 205 🖥️ Hybrid

Tracy Fisher and Lacey Langlois, Canadian Institute for Health Information



Notes

 **Friday, September 6**

Early Morning Sessions

7:45 a.m. – 8:30 a.m.

Tackling Environmental Impacts in Health Care Systems and in Health Technology Assessment Agencies Toward 2030: Where Do We Stand With 6 Years Left?

 Level 2 – Room 207  Hybrid

Corelia Kostovic, INESSS

What's New in US HTA? A Snapshot of ICER's Value Assessment Framework Update

 Level 3 – Canada Hall 1  Hybrid

Daniel Ollendorf and Marina Richardson, Institute for Clinical and Economic Review (ICER)

Panel Sessions

8:45 a.m. – 10:00 a.m.

Closing the Gap or Widening the Divide: Do We Need a Framework for Truly Embedding Equity in Health Technology Assessment (HTA)?

 Level 2 – Room 207  Hybrid

Jonathan Pearson-Stuttard, Lane Clark & Peacock LLP (Moderator); Stephen Duffield, National Institute for Health and Care Excellence; Susan Griffin, University of York; Chris Lubker, Novo Nordisk; Marina Richardson, Institute for Clinical and Economic Review

Improving Patient Safety and Outcomes: A Vision for a Pan-Canadian Coordinated Approach to Appropriate Use

 Level 3 – Canada Hall 1  Hybrid

Connie Newman, Lived Experience Partner, Canada's Drug Agency Appropriate Use Advisory Committee; Stephen Samis, Co-Chair, Canada's Drug Agency Appropriate Use Advisory Committee; Jim Silvius, Co-Chair, Canada's Drug Agency Appropriate Use Advisory Committee; and Sudha Kutty, Canada's Drug Agency (Moderator)

Notes



📅 Friday, September 6

Panel Sessions

8:45 a.m. – 10:00 a.m.

An Innovative and Learning Health System Fuelled by Digital and Technological Transformation – Recent Successes From the Nova Scotia Health Cancer Care Program

📍 Level 2 – Room 206 🖥️ Hybrid

Amanda Caissie, Nova Scotia Health; Doris Grant, Life Sciences Nova Scotia

From Disruption to Opportunity: What Can HTA Learn From Taylor Swift?

📍 Level 2 – Room 205 🖥️ Hybrid

Nancy Sikich, Ontario Health (Moderator); Laura Weeks, Canada’s Drug Agency; Wendy Ungar, Technology Assessment at SickKids (TASK), Hospital for Sick Children Research Institute; Kali Barrett, THETA; Maggie Keresteci, CAHSPR; Paul Bradley, Medtech Consulting; Jovan Matic, Government of Ontario

Doing More Together: Aging With Dignity and in Place – Working Together Across PCHOs and Canada

📍 Level 2 – Room 201 🖥️ Hybrid

Tanya MacDonald, Healthcare Excellence Canada; Maria Judd, Healthcare Excellence Canada (Moderator); Gino De Angelis, Canada’s Drug Agency; Alesha Gaudet, Department of Social Development, New Brunswick

☕ **Networking Break** ☕



Notes

 **Friday, September 6**

Oral Presentations

10:30 a.m. – 11:30 a.m.

Diverse Perspectives

 Level 2 – Room 207  Hybrid

Prioritizing Community Partnerships: A Collaborative Approach to Promoting Medication Appropriateness Across Diverse British Columbia Communities
Leslie Gaudette, Council of Senior Citizens' Organizations of British Columbia

Advancing Justice-Oriented Patient Engagement in Health Technology Assessment
Roma Dhamanaskar, McMaster University

Public Preferences for Improving Health Equity in Canada: A Qualitative Focus Group Study
Christopher Cadham, University of Michigan

Indigenizing Medication Appropriateness in Canada: Charting a Path Towards Equity and Healing
Cheryl A. Sadowski, University of Alberta

Maximizing the Impact of HTA

 Level 3 – Canada Hall 1  Hybrid

Improving the Impact of Health Technology Assessment (HTA) in Canada
Craig Mitton, University of British Columbia

An Actionable and Legible Toolbox for the Appraisal of Health Care Innovations Developed Through Provincial Stakeholder Collaboration
Pascale Lehoux, INESSS

Aligning Deliberative Frameworks at Canada's Drug Agency
Deirdre DeJean, Canada's Drug Agency

HTA Methods

 Level 2 – Room 205  Hybrid

Use of Bayesian Hierarchical Models in Economic Evaluations
Petros Pechlivanoglou, The Hospital for Sick Children (SickKids) Research Institute

Humanizing HTA Practices: The INESSS Users' and Relatives' Panel
Louis Lochhead and Marie-Pascale Pomey, INESSS

Understanding and Measuring Health Outcomes in Children With Rare Genetic Conditions
Jeff Round, Institute of Health Economics



📅 Friday, September 6

Oral Presentations

10:30 a.m. – 11:30 a.m.

Health Economics

📍 Level 2 – Room 206 🖥️ Hybrid

Model-Based Estimates of the Cost of Obstetric Evacuation for Fly-In First Nation Communities in Ontario

Majd Radhaa, Western University

Identifying High-Cost Users in Ontario: Implications of Follow-Up Time and Censoring for Measuring High-Cost Users Using Administrative Data

Kali Barrett, University of Toronto

Integrating Lived Experience: Developing a Theoretical and Methodological Approach to Conducting an Institutional Ethnography for Economic Evaluations

Chantal Valiquette, University of Toronto

23 and (Not Just) Me: Incorporating Family Members in Economic Evaluation of Genetic Testing Technologies

Wendy Ungar, Technology Assessment at SickKids (TASK), Hospital for Sick Children Research Institute

Medical Devices

📍 Level 2 – Room 201 🧑 In-Person Only

Level 2 Polysomnography for the Diagnosis of Sleep Disorders: An HTA

Samrawit Lemma, Stacey Vandersluis, Nancy Sikich, Ontario Health (OH)

The Canadian Medical Imaging Inventory (CMII): A Decade of Difference

Andra Morrison, Canada's Drug Agency

How To Conduct Agile Reviews of Medical Devices for the Management of Diabetes

Julie Nieminen, INESSS

🍷 Networking Break 🍷


Notes

 **Friday, September 6**

Closing Plenary

12:00 p.m. – 1:15 p.m.

**From Disruption To Opportunity:
How AI Is Changing Health Care and HTA**

 Level 3 – Canada Hall 1  Hybrid

From drug development to diagnostic imaging to robotic surgery, artificial intelligence (AI) is having a profound effect on health care. AI is also changing how HTA organizations do their work and challenging them to consider different elements when assessing technologies that use AI. An international panel of senior HTA leaders will share their insights and experiences on how AI is being incorporated into HTA processes and how HTA can effectively address AI to create opportunities for improved patient outcomes and cost-effective health care delivery. They will discuss why disruptive innovation is needed, the potential risks and benefits of AI, and what jurisdictions around the world are doing to adapt to these new challenges. Attendees will gain valuable insights into the role of HTA in embracing change and driving innovation in health care. They will leave with a deeper understanding of how HTA can help health care systems adapt to disruptions, seize opportunities, and ultimately improve patient outcomes and the sustainability of health care delivery.

- **Muhammad Mamdani**, Vice-President, Data Science and Advanced Analytics at Unity Health Toronto (Moderator)
- **Nick Crabb**, Chief Scientific Officer, National Institute for Health and Care Excellence (NICE)
- **Irena Guzina**, Scientific Project Manager, Haute Autorité de Santé (HAS)
- **Pascale Lehoux**, Vice-Présidente Scientifique, INESSS
- **Nicole Mittmann**, Chief Scientist and Vice-President, Scientific Evidence, Methodologies, and Resources, Canada's Drug Agency
- **Dan Ollendorf**, Chief Scientific Officer and Director of HTA Methods Development, Institute for Clinical and Economic Review (ICER)

Notes



Symposium 2024

Friday, September 6

Closing

1:15 p.m. – 1:30 p.m.

Presentation Of the Student Poster Award And Official Closing

📍 Level 3 – Canada Hall 1 🖥️ Hybrid

Suzanne McGurn, President and CEO, Canada's Drug Agency

Networking Event

1:30 p.m. – 2:30 p.m.

Closing Reception

📍 Level 3 – Parliament Foyer 2 🧑 In-Person Only

Join us for the grand finale of Symposium 2024 at the closing reception! Unwind and network with fellow attendees. Celebrate the culmination of insightful discussions and fruitful connections in a relaxed and inviting atmosphere. Don't miss this opportunity to toast the success of another memorable Symposium experience! Delectable appetizers and a cash bar will be available.

TACT

Accès au marché

Évaluation des technologies de la santé

Évaluation clinique et pharmacoeconomique

Services conseils stratégiques canadiens et spécifiques pour le Québec

Stratégie pour la négociation d'entente d'inscription

Relations gouvernementales

Relations publiques

Market access

Health technology assessment

Clinical and pharmacoeconomic evaluation

Canadian and Quebec specific strategic consulting services

Negotiation strategies for listing agreement

Government relations

Public relations

Une équipe professionnelle de plus de 100 personnes alliant réflexion et résultats.

More than 100 audacious yet humble professionals.

Incluant / including :

Patrick Manfred
Vice-président
Vice President



Dan Cooper
Vice-président
Vice President





QUALITY WORK • VALUABLE RESULTS

**HEALTH ECONOMICS
HEALTH OUTCOMES
PRICING
ADVISORY BOARDS
REIMBURSEMENT**



www.pivina.com

PIVINA Consulting Inc.



Thank You

Canada's Drug Agency would like to acknowledge the hard work of the many volunteers who contributed to the success of Symposium 2024.

Abstract Reviewers

Denise Adams
Ilke Akpınar
Sarah Alakshar
Mohammadreza Amiri
Farhat Batool
Ann Besner
Artri Bhasin
Lorraine Boyle
Noor Breik
Sheila Burns
Zafer Çalıřkan
Kim Castellano
Anthone Chen
Autumn Chen
Stephanie Cheng
Alicia Chin
Stephen Congly
Tessa Cornelissen
Suzanne Deliscar
Amandeep Dhanoa
Robert Deonarine
Matthew Dick
Anar Dossa
Jenna Esteban Villarba
Tanya Ewashko
Julie Farmer
Naghmeħ Foroutan
Julius Fru Che
Marie-Eve Gagnon
Rose Gagnon
Olga Gajic-Veljanoski
Allison Gates
Étienne Gaudette
Alana Gaumont

Scott Gavura
Kristina Gentes
AurÉlie Godbout
Jason Guertin
Shalak Gunjal
Jennifer Guo
Samuel Hackett
Filimon Haile
Shazia Hassan
Adam Haynes
Sarah Himelfarb-Blyth
Victoria Hodgkinson
Anne Holbrook
Matthew Hudson
Trudy Huyghebaert
Sarah Jennings
Matt Joosse
Ishita Joshi
Izabella Kaczmarek
Sandra Ketler
Mrinmoy Kundu
Mehdi Larbi
Matt Lee
Erica Lester
Janet Leung
Joel Lexchin
Thomas Luong
Siddhi Manjrekar
Abdullah Al Maruf
Jeff Mason
Joyce Mason
Lisa Masucci
Edward Mawejje
Valerie McDonald
Brendan McIntosh

Rebecca Mercer
Chloe Mighton
Rohini Naipaul
Kukuh Noertjojo
Darren Pasay
Reka Pataky
Kayley Perfetto
Yeesha Poon
Denise Prindiville
Muhammad İlham Dhiya Rakasiwi
Sreeram Ramagopalan
Kripa Raman
Michelle Rey-Lloyd
Danika Rivet
Raina Rogoza
Chiranjeev Sanyal
Hailey Saunders
Tara Schuller
Anna Scott
Ashleen Shadeo
Dori Simeonov
Jeremy Slayter
Laura Smith van Carroll
Malcolm Snow
G. Nathalie Sombie
Anusree Subramonian
Shannon Sullivan
Sam Sutherland
Mina Tadrous
Andrea Tang
Dipti Tankala
Kednapa Thavorn
Chantale Thurston
Eon Ting
Carlos Toro-Huamanchumo

Eva Tsakonas
Sheila Tucker
Rachel Vanderploeg
Dominique Vervoort
Catherine Virelli
David Whitehurst
Kary Yau
Juliana Yi
Kim Yoong
Simon Yunger
Yuan Zhang
Nancy Zorzi

Graphic Design

Chris Mantil
Jessica Gerwing
BOLD LIP

Symposium 2024 Team


Peter Chinneck
Ayan Ibrahim
Josée Nugent
Leeyaa Patel

Recognition Awards Selection Committee

David Agnew
Louise Bird
Stirling Bryan
Leslie Anne Campbell
Karen Lee
Suzanne McGurn
Nicole Mittmann
Kednapa Thavorn
Wendy Ungar

Program Advisory Committee

Randy Allan
Yannick Auclair
Ken Bond
Michael Dietrich
Peter Dyrda
Sandra Ketler
Karen Lee
Chunmei Li
Raj Malik
Ben Peacock
Hamid Sadri
Camilla Tajzler



Symposium 2024



Shaw Centre
55 Colonel By Drive

Location Map

- | | | | | | |
|----|--|----|---|----|---|
| 01 | CF Rideau Centre
50 Rideau Street | 04 | National War Memorial
Wellington Street | 07 | Parliament Hill
Wellington Street |
| 02 | National Art Centre
1 Elgin Street | 05 | Ottawa Art Gallery
50 Mackenzie King Bridge | 08 | Major's Hill Park
Mackenzie Avenue |
| 03 | Confederation Park
Elgin Street | 06 | Château Laurier
1 Rideau Street | 09 | ByWard Market
55 Byward Market Square |

The logo for Cencora, featuring the word "cencora" in a lowercase, sans-serif font.

Innomar Strategies

Elevate your market access strategy with InnomarConsulting™

Navigate the complexities of the reimbursement landscape with ease

At Innomar Strategies, we specialize in a comprehensive suite of services designed to streamline your path to market and enhance your strategic positioning. Our expertise includes:


- **Market Access Strategy:** Tailored strategies to navigate complex Canadian market access and pricing landscape for product launches
- **HTA/Payer Submissions:** Expert guidance and support for health technology assessments and payer submissions
- **HEOR and RWE:** Robust health economics and outcomes research (HEOR) combined with real-world evidence (RWE) to demonstrate value
- **Market Research:** In-depth market insights to inform your strategic decisions
- **Data Insights:** Advanced data analysis to drive informed strategies

By working with Innomar Strategies, you also gain access to integrated services that cover every aspect of the product lifecycle, including regulatory and quality assurance services. We help existing manufacturers as well as those new to Canada develop effective commercialization strategies so patients can gain access to the latest advances in healthcare.

Ready to transform your market approach?

Visit www.innomar-strategies.com to learn more about how we can support your journey from innovation to impact.

For any inquiries, please contact: Michelle O'Connor Coughlan, Director, NBD, Regulatory Affairs and Strategic Consulting at michelle.oconnorcoughlan@cencora.com.





**Canada's
Drug
Agency**

**L'Agence des
médicaments
du Canada**

Drugs.
Health Technologies
and Systems.

Médicaments,
technologies de la santé
et systèmes.

Canada's Drug Agency is a pan-Canadian health organization.

Created and funded by Canada's federal, provincial, and territorial governments, we're responsible for driving better coordination, alignment, and public value within Canada's drug and health technology landscape.

We provide Canada's health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact.

cda-amc.ca